Who are the key players in Breast Cancer Therapy Market?

Novartis AG, Merck Co & Inc., Fresenius Kabi, Pfizer Inc. and Eli Lilly & Co. are the major companies operating in the Breast Cancer Therapy Market. Read More

Which is the fastest growing region in Breast Cancer Therapy Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Breast Cancer Therapy Market?

In 2024, the North America accounts for the largest market share in Breast Cancer Therapy Market. Read More

What years does this Breast Cancer Therapy Market cover, and what was the market size in 2023?

In 2023, the Breast Cancer Therapy Market size was estimated at USD 28.50 billion. The report covers the Breast Cancer Therapy Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Breast Cancer Therapy Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Breast Cancer Therapy Market Size

Market Size of Breast Cancer Therapy Industry

Study Period	2019 - 2029
Market Size (2024)	USD 30.70 Billion
Market Size (2029)	USD 43.40 Billion
CAGR (2024 - 2029)	7.17 %
Fastest Growing Market	Asia-Pacific
Largest Market	North America
Major Players *Disclaimer: Major Players sorted in no particular order

Breast Cancer Therapy Market Analysis

The Breast Cancer Therapy Market size is estimated at USD 30.70 billion in 2024, and is expected to reach USD 43.40 billion by 2029, growing at a CAGR of 7.17% during the forecast period (2024-2029).

The major factors fueling the market's growth are the high incidence and prevalence rates of breast cancer, increasing investment in research and development, and advancements in cancer biology and pharmacology, promoting drug development.

According to Globocan, in 2020, about 2,261,419 new cancer cases were reported worldwide, contributing to about 11.7% of the total cancer cases. As per canceraustralia.gov.au, in 2021, 20,030 new breast cancer cases were diagnosed in the country (164 males and 19,866 females). The same source reports that in 2021, a person had an estimated 1 in 15 (or 6.7%) risk of being diagnosed with breast cancer by the age of 85 (1 in 8 or 13% for females and 1 in 829 or 0.12% for males). Therefore, the high burden of breast cancer is increasing the demand for breast cancer treatment, thereby contributing to the market's growth.

The increasing focus of research studies by the market players. For instance, in September 2021, Novartis AS collaborated with Solti on HARMONIA, an international, randomized, Phase III, multicenter, and open-label study of Kisqali (ribociclib) versus Ibrance (palbociclib), both in combination with endocrine therapy. This study was on patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer with a HER2-enriched (HER2E) intrinsic subtype.

Increasing launches by manufacturers to meet the growing demand for innovative products are expected to drive market growth. For instance, in July 2021, Arvinas Inc. and Pfizer Inc. collaborated to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. Such factors potentially drive the demand for the adoption of breast cancer therapy worldwide.

On the other hand, the risk of adverse effects of radiation exposure and stringent regulatory scenarios are hindering the market's growth.

Breast Cancer Therapy Industry Segmentation

As per the scope of this report, breast cancer therapy refers to cancer treatment with chemotherapy, targeted therapy, hormonal therapy, etc. These therapies block the growth and proliferation of cancer by interfering with specific molecules, such as DNA or proteins, that are involved in the growth or expansion of cancerous cells. The breast cancer therapy market is segmented by therapy (radiation therapy, targeted therapy, hormonal therapy, and chemotherapy) and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the market sizes and forecasts in terms of value (USD million) for the above segments.

By Therapy

Radiation Therapy

Targeted Therapy
	Herceptin
	Tykerb (Lapatinib)
	Afinitor
	Other Targeted Therapies

Hormonal Therapy
	Selective Estrogen - Receptor Modulators
	Aromatase Inhibitors
	Other Hormonal Therapies

Chemotherapy
	Taxanes
	Anthracyclines
	Anti-metabolites
	Alkylating Agents
	Epothilones

Geography

North America
	United States
	Canada
	Mexico

Europe
	Germany
	United Kingdom
	France
	Italy
	Spain
	Rest of Europe

Asia-Pacific
	China
	Japan
	India
	Australia
	South Korea
	Rest of Asia-Pacific

Middle East and Africa
	GCC
	South Africa
	Rest of Middle East and Africa

South America
	Brazil
	Argentina
	Rest of South America

Need A Different Region Or Segment?

Customize Now

Breast Cancer Therapy Market Size Summary

The breast cancer therapy market is poised for significant growth over the forecast period, driven by the high incidence and prevalence of breast cancer globally. The market is experiencing a surge in demand due to increased awareness and the rising burden of the disease, which is prompting substantial investments in research and development. Advancements in cancer biology and pharmacology are further propelling drug development, with numerous innovative therapies being introduced to meet the growing needs of patients. Collaborative efforts among major players, such as Novartis and Pfizer, are enhancing the development of targeted therapies, while regulatory approvals in regions like the United States are boosting market confidence and expansion.

North America, particularly the United States, is expected to dominate the breast cancer therapy market, supported by a high incidence rate and a robust pipeline of new products. The competitive landscape is marked by the presence of major pharmaceutical companies, including Novartis AG, Pfizer Inc., and Merck & Co. Inc., which are actively involved in developing and commercializing advanced therapies. The market's growth is also fueled by the increasing number of product launches and the approval of novel treatments, such as Enhertu for HER2-low breast cancer, which address specific subtypes of the disease. Despite challenges like the risk of adverse effects from treatments and stringent regulatory environments, the market is set to expand, driven by ongoing innovation and strategic collaborations.

Explore More

Breast Cancer Therapy Market Size - Table of Contents

1. MARKET DYNAMICS
1. 1.1 Market Overview
2. 1.2 Market Drivers
  1. 1.2.1 High Incidence and Prevalence Rate of Breast Cancer
  2. 1.2.2 Increasing Investments in R&D
  3. 1.2.3 Advancements in Cancer Biology and Pharmacology, Promoting Drug Development
3. 1.3 Market Restraints
  1. 1.3.1 Risk of Adverse Effects of Radiation Exposure
  2. 1.3.2 Stringent Regulatory Scenarios
4. 1.4 Porter's Five Forces Analysis
  1. 1.4.1 Bargaining Power of Suppliers
  2. 1.4.2 Bargaining Power of Buyers/Consumers
  3. 1.4.3 Threat of New Entrants
  4. 1.4.4 Threat of Substitute Products
  5. 1.4.5 Intensity of Competitive Rivalry
2. MARKET SEGMENTATION (Market Size by Value - USD million)
1. 2.1 By Therapy
  1. 2.1.1 Radiation Therapy
  2. 2.1.2 Targeted Therapy
    1. 2.1.2.1 Herceptin
    2. 2.1.2.2 Tykerb (Lapatinib)
    3. 2.1.2.3 Afinitor
    4. 2.1.2.4 Other Targeted Therapies
  3. 2.1.3 Hormonal Therapy
    1. 2.1.3.1 Selective Estrogen - Receptor Modulators
    2. 2.1.3.2 Aromatase Inhibitors
    3. 2.1.3.3 Other Hormonal Therapies
  4. 2.1.4 Chemotherapy
    1. 2.1.4.1 Taxanes
    2. 2.1.4.2 Anthracyclines
    3. 2.1.4.3 Anti-metabolites
    4. 2.1.4.4 Alkylating Agents
    5. 2.1.4.5 Epothilones
2. 2.2 Geography
  1. 2.2.1 North America
    1. 2.2.1.1 United States
    2. 2.2.1.2 Canada
    3. 2.2.1.3 Mexico
  2. 2.2.2 Europe
    1. 2.2.2.1 Germany
    2. 2.2.2.2 United Kingdom
    3. 2.2.2.3 France
    4. 2.2.2.4 Italy
    5. 2.2.2.5 Spain
    6. 2.2.2.6 Rest of Europe
  3. 2.2.3 Asia-Pacific
    1. 2.2.3.1 China
    2. 2.2.3.2 Japan
    3. 2.2.3.3 India
    4. 2.2.3.4 Australia
    5. 2.2.3.5 South Korea
    6. 2.2.3.6 Rest of Asia-Pacific
  4. 2.2.4 Middle East and Africa
    1. 2.2.4.1 GCC
    2. 2.2.4.2 South Africa
    3. 2.2.4.3 Rest of Middle East and Africa
  5. 2.2.5 South America
    1. 2.2.5.1 Brazil
    2. 2.2.5.2 Argentina
    3. 2.2.5.3 Rest of South America